The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants
as relapse prevention for patients that are completing treatment for opiate addiction in
inpatient (or similarly controlled) settings. Participants in the naltrexone experimental
group are prematched in a pairwise fashion with other patients who do not want a naltrexone
implant during the first six months after ending inpatient treatment, but who reiceive
treatment as usual (TAU) from the Norwegian healthcare system.
The hypotheses are that quality of life, depression, opioid use, will be significantly better
in the naltrexone group compared to the non at 6-, 12-, and 18-month follow-up.
We also hypothesize that the implants can prevent death from opioid overdose up to 6 months
after commenced treatment.